GlassScriptPhysician profile
Robbie Rae Leinart
NPI 1770617011
$47,848.53
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,329 · 2022: $4,864 · 2023: $3,539 · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $6,410 · Travel and Lodging: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,642.50 |
| Food and Beverage | $6,409.64 |
| Travel and Lodging | $602.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22,374.87 | 2023-2025 | Voquezna |
| Abbvie INC. | $18,586.81 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,865.02 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,332.85 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $905.43 | 2021-2025 | Stelara, Simponi Aria, Remicade |
| Nestle Healthcare Nutrition INC. | $451.21 | 2021-2023 | |
| Ardelyx, INC. | $291.40 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $270.51 | 2021-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $217.58 | 2021-2024 | Ocaliva |
| Gilead Sciences, INC. | $214.70 | 2021-2024 | |
| Qol Medical, LLC | $155.59 | 2021-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $143.30 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $123.21 | 2021-2024 | Linzess |
| Genzyme Corporation | $116.42 | 2023-2024 | |
| Pfizer INC. | $109.71 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $91.01 | 2021-2022 | |
| Daiichi Sankyo INC. | $81.76 | 2021-2023 | Injectafer |
| Intra-Sana Laboratories | $68.60 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Vivus LLC | $62.52 | 2021-2022 | |
| Celgene Corporation | $58.67 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $58.26 | 2021-2022 | |
| Lilly USA, LLC | $51.75 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $44.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.74 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $38.85 | 2024 | |
| Braintree Laboratories, INC. | $31.87 | 2022-2024 | Suflave, Sutab |
| Amgen INC. | $19.25 | 2021 | |
| Fresenius Kabi USA, LLC | $16.68 | 2024 | Idacio |
| Pharmacosmos Therapeutics INC. | $14.05 | 2021 | |
| Evoke Pharma, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robbie Leinart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.